Rabbit Polyclonal ERK5 antibody. Suitable for WB, IHC-P and reacts with Pig, Human samples. Immunogen corresponding to Recombinant Fragment Protein within Human MAPK7 aa 550-800.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 55.77% Glycerol (glycerin, glycerine), 44.12% PBS
WB | IHC-P | |
---|---|---|
Human | Tested | Tested |
Pig | Tested | Expected |
Species | Dilution info | Notes |
---|---|---|
Species Pig | Dilution info 0.2-2 µg/mL | Notes - |
Species Human | Dilution info 0.2-2 µg/mL | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 5-20 µg/mL | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Pig | Dilution info Use at an assay dependent concentration. | Notes - |
Select an associated product type
Plays a role in various cellular processes such as proliferation, differentiation and cell survival. The upstream activator of MAPK7 is the MAPK kinase MAP2K5. Upon activation, it translocates to the nucleus and phosphorylates various downstream targets including MEF2C. EGF activates MAPK7 through a Ras-independent and MAP2K5-dependent pathway. As part of the MAPK/ERK signaling pathway, acts as a negative regulator of apoptosis in cardiomyocytes via interaction with STUB1/CHIP and promotion of STUB1-mediated ubiquitination and degradation of ICER-type isoforms of CREM (By similarity). May have a role in muscle cell differentiation. May be important for endothelial function and maintenance of blood vessel integrity. MAP2K5 and MAPK7 interact specifically with one another and not with MEK1/ERK1 or MEK2/ERK2 pathways. Phosphorylates SGK1 at Ser-78 and this is required for growth factor-induced cell cycle progression. Involved in the regulation of p53/TP53 by disrupting the PML-MDM2 interaction.
BMK1, ERK5, PRKM7, MAPK7, Mitogen-activated protein kinase 7, MAP kinase 7, MAPK 7, Big MAP kinase 1, Extracellular signal-regulated kinase 5, BMK-1, ERK-5
Rabbit Polyclonal ERK5 antibody. Suitable for WB, IHC-P and reacts with Pig, Human samples. Immunogen corresponding to Recombinant Fragment Protein within Human MAPK7 aa 550-800.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 55.77% Glycerol (glycerin, glycerine), 44.12% PBS
ab232748 was purified by antigen-specific affinity chromatography followed by Protein A affinity chromatography.
ERK5 also known as big MAP kinase 1 (BMK1) is an enzyme that functions as a protein-serine/threonine kinase within the MAP kinase family. It has a molecular weight of approximately 120 kDa. ERK5 is expressed in various tissues including the brain heart and lungs with notable expression in endothelial cells. The protein plays a mechanical role in signal transduction processes which it achieves by transmitting signals from extracellular sources to the cellular nucleus facilitating the regulation of gene expression.
ERK5 influences cellular functions through its role in promoting cell proliferation and differentiation. It serves as part of a signaling complex that includes the MAP kinase kinase 5 (MEK5). This interaction allows ERK5 to phosphorylate and subsequently activate target substrates such as transcription factors promoting cellular responses necessary for development and survival. ERK5 also plays a role in the response to oxidative stress which contributes to its impact on survival pathways and cellular stress responses.
ERK5 acts within the MAPK signaling cascade and is linked to the ERK/MAPK pathway and the phosphoinositide 3-kinase (PI3K) pathway. Within these pathways ERK5 interacts with other MAP kinases and regulatory proteins such as Ras and Raf contributing to a wide range of cellular processes including growth migration and survival. Through these interactions ERK5 influences cellular dynamics and mediates responses to growth factors and stress stimuli.
Abnormal activity of ERK5 has been implicated in various conditions including cardiovascular disease and cancer. Elevated ERK5 signaling can promote tumor progression and metastasis in certain cancers by enhancing tumor cell proliferation and survival. In cardiovascular disorders ERK5 interacts with proteins like calcium/calmodulin-dependent protein kinase II (CaMKII) influencing pathological cardiac remodeling and hypertrophy. These associations highlight ERK5's impact on disease mechanisms and highlight its potential as a therapeutic target.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Paraffin-embedded human colorectal cancer tissue stained for ERK5 using ab232748 at 20 μg/ml in immunohistochemical analysis. DAB staining.
Paraffin-embedded human lung cancer tissue stained for ERK5 using ab232748 at 20 μg/ml in immunohistochemical analysis. DAB staining.
Paraffin-embedded human kidney tissue stained for ERK5 using ab232748 at 20 μg/ml in immunohistochemical analysis. DAB staining.
All lanes: Western blot - Anti-ERK5 antibody (ab232748) at 2 µg/mL
All lanes: Recombinant human ERK5 protein
Predicted band size: 26 kDa, 88 kDa
All lanes: Western blot - Anti-ERK5 antibody (ab232748) at 2 µg/mL
All lanes: Pig colon tissue lysate
Predicted band size: 88 kDa
All lanes: Western blot - Anti-ERK5 antibody (ab232748) at 2 µg/mL
All lanes: HeLa (human epithelial cell line from cervix adenocarcinoma) cell lysate
Predicted band size: 88 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com